CABALETTA BIO, INC. Financing Cash Flow
CABALETTA BIO, INC. (CABA) reported Financing Cash Flow of $175.25 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- CABALETTA BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $149.99M, a 60.63% increase year-over-year.
- CABALETTA BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $25.27M.
- CABALETTA BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $8.33M, a 90.58% increase year-over-year.
- CABALETTA BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$806.00K, a 1235.21% decline year-over-year.
- CABALETTA BIO, INC. net cash provided by (used in) financing activities for fiscal 2025 was $100.35M, a 759.36% increase from fiscal 2024.
- CABALETTA BIO, INC. net cash provided by (used in) financing activities for fiscal 2024 was $11.68M, a 93.78% decline from fiscal 2023.
- CABALETTA BIO, INC. net cash provided by (used in) financing activities for fiscal 2023 was $187.63M, a 468.89% increase from fiscal 2022.
- CABALETTA BIO, INC. net cash provided by (used in) financing activities for fiscal 2022 was $32.98M, a 32.56% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $149.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $175.25M 10-Q · filed 2026-08-13 | $183.59M derived: sum of 3 quarters · filed 2026-08-13 | $182.78M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $25.27M 10-Q · filed 2026-05-14 | $33.60M derived: sum of 2 quarters · filed 2026-05-14 | $32.79M derived: sum of 3 quarters · filed 2026-05-14 | $126.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $8.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $7.53M derived: sum of 2 quarters · filed 2026-03-23 | $100.90M derived: sum of 3 quarters · filed 2026-08-13 | $100.35M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$806.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $92.57M derived: sum of 2 quarters · filed 2026-08-13 | $92.02M 10-Q · filed 2025-11-10 | $96.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $93.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $92.82M 10-Q · filed 2026-08-13 | $97.19M derived: sum of 3 quarters · filed 2026-08-13 | $97.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$552.00K 10-Q · filed 2026-05-14 | $3.82M derived: sum of 2 quarters · filed 2026-05-14 | $3.89M derived: sum of 3 quarters · filed 2026-05-14 | $4.27M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $4.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $4.44M derived: sum of 2 quarters · filed 2026-03-23 | $4.82M derived: sum of 3 quarters · filed 2026-03-23 | $11.68M 10-K · filed 2026-03-23 |
| 2024-09-30 | $71.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $450.00K derived: sum of 2 quarters · filed 2025-11-10 | $7.30M 10-Q · filed 2025-11-10 | $100.35M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $379.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $7.23M 10-Q · filed 2025-08-07 | $100.28M derived: sum of 3 quarters · filed 2025-08-07 | $100.38M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $6.86M 10-Q · filed 2025-05-15 | $99.90M derived: sum of 2 quarters · filed 2025-05-15 | $100.00M derived: sum of 3 quarters · filed 2025-05-15 | $194.26M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $93.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $93.15M derived: sum of 2 quarters · filed 2025-03-31 | $187.41M derived: sum of 3 quarters · filed 2025-03-31 | $187.63M 10-K · filed 2025-03-31 |
| 2023-09-30 | $98.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $94.36M derived: sum of 2 quarters · filed 2024-11-14 | $94.58M 10-Q · filed 2024-11-14 | $127.47M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $94.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $94.48M 10-Q · filed 2024-08-08 | $127.38M derived: sum of 3 quarters · filed 2024-08-08 | $127.38M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $226.00K 10-Q · filed 2024-05-15 | $33.12M derived: sum of 2 quarters · filed 2024-05-15 | $33.12M derived: sum of 3 quarters · filed 2024-05-15 | $33.16M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $32.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $32.89M derived: sum of 2 quarters · filed 2024-03-21 | $32.93M derived: sum of 3 quarters · filed 2024-03-21 | $32.98M 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $40.00K derived: sum of 2 quarters · filed 2023-11-09 | $91.00K 10-Q · filed 2023-11-09 | $13.72M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $91.00K 10-Q · filed 2023-08-10 | $13.72M derived: sum of 3 quarters · filed 2023-08-10 | $39.06M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $51.00K 10-Q · filed 2023-05-11 | $13.68M derived: sum of 2 quarters · filed 2023-05-11 | $39.02M derived: sum of 3 quarters · filed 2023-05-11 | $46.79M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $13.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $38.97M derived: sum of 2 quarters · filed 2023-03-16 | $46.74M derived: sum of 3 quarters · filed 2023-03-16 | $48.90M 10-K · filed 2023-03-16 |
| 2021-09-30 | $25.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $33.11M derived: sum of 2 quarters · filed 2022-11-10 | $35.27M 10-Q · filed 2022-11-10 | $35.31M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $7.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $9.94M 10-Q · filed 2022-08-11 | $9.97M derived: sum of 3 quarters · filed 2022-08-11 | $10.10M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $2.17M 10-Q · filed 2022-05-12 | $2.20M derived: sum of 2 quarters · filed 2022-05-12 | $2.33M derived: sum of 3 quarters · filed 2022-05-12 | $2.19M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $167.00K derived: sum of 2 quarters · filed 2022-03-17 | $20.00K derived: sum of 3 quarters · filed 2022-03-17 | -$24.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $135.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | -$12.00K derived: sum of 2 quarters · filed 2021-11-01 | -$56.00K 10-Q · filed 2021-11-01 | $73.26M derived: sum of 4 quarters · filed 2021-11-01 |
| 2020-06-30 | -$147.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$191.00K 10-Q · filed 2021-08-05 | $73.13M derived: sum of 3 quarters · filed 2021-08-05 | $71.03M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$44.00K 10-Q · filed 2021-05-03 | $73.28M derived: sum of 2 quarters · filed 2021-05-03 | $71.17M derived: sum of 3 quarters · filed 2021-05-03 | $70.22M derived: sum of 4 quarters · filed 2021-05-03 |
| 2019-12-31 | $73.32M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $71.22M derived: sum of 2 quarters · filed 2021-03-16 | $70.26M derived: sum of 3 quarters · filed 2021-03-16 | $119.92M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$3.06M derived: sum of 2 quarters · filed 2020-11-10 | $46.61M 10-Q · filed 2020-11-10 | $71.75M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | -$956.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $48.71M 10-Q · filed 2020-08-06 | $73.85M derived: sum of 3 quarters · filed 2020-08-06 | |
| 2019-03-31 | $49.66M 10-Q · filed 2020-05-12 | $74.81M derived: sum of 2 quarters · filed 2020-05-12 | ||
| 2018-12-31 | $25.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $37.68M 10-K · filed 2020-03-30 | ||
| 2018-09-30 | $12.54M 10-Q · filed 2019-12-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |